Brief: Reviva Pharmaceuticals Previous Financial Statements For FY 2022, Interim Financial Statements Quarter Ended Sept 30, 2022, No Longer Be Relied Upon

Reviva Pharmaceuticals Holdings

15/04/2024 13:09

April 15 (Reuters) - Reviva Pharmaceuticals Holdings,
Inc.  RVPH.O :
    * REVIVA PHARMACEUTICALS: PREVIOUS FINANCIAL STATEMENTS FOR
FY
2022, INTERIM FINANCIAL STATEMENTS QUARTER ENDED SEPT 30, 2022,
NO LONGER BE RELIED UPON
    * REVIVA PHARMACEUTICALS HOLDINGS, INC.: INTERIM FINANCIAL
STATEMENTS FOR QUARTERLY PERIODS IN FY 2023 SHOULD NO LONGER BE
RELIED UPON
    * REVIVA PHARMACEUTICALS: PREVIOUSLY-ISSUED FINANCIAL
STATEMENTS
FOR FY 2022 HAD UNDERSTATED BY ABOUT $3.9 MILLION CERTAIN
RESEARCH & DEVELOPMENT EXPENSES
    * REVIVA PHARMACEUTICALS: PRINCIPALLY ATTRIBUTES ERRORS TO
MATERIAL WEAKNESSES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
& CLINICAL TRIAL EXPENSES

Source text for Eikon:  ID:n0001437749-24-011948 
Further company coverage:  RVPH.O 

 ((Reuters.Briefs@thomsonreuters.com;))